Pfizer applies for reimbursement of 3rd-gen ALKi Lorviqua
By Eo, Yun-Ho | translator Alice Kang
21.10.19 15:26:04
가나다라
0
Designated as an orphan drug… is in its listing process after being approved in July
Is expected to address drug resistance issue of previously introduced drugs, including ‘Xalkori’
According to industry sources, Pfizer Korea has recently submitted a reimbursement listing application for its anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), ‘Lorviqua (lorlatinib),’ which is in progress.
Pfizer received the orphan drug designation for Lorviqua last March, then in July, the drug was approved as monotherapy to treat adult patients with ALK-positive advanced non-small-cell lung cancer (NSCLC) whose disease has progressed after - Alecensa (alectinib) or Zykadia (ceritinib) as the first ALK tyrosine kinase inhibitor (TKI) therapy; or Xalkori (crizot
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)